Stock Evaluator: Acurx Pharmaceuticals, Inc. (ACXP)

Acurx Pharmaceuticals, Inc. ACXP

$1.06 -0.03 -2.30%
October 27, 2026 4:00:00 PM EST November 10, 2021 Volume: 58,273
After Hours: $120.37   0.15  |  0.12% November 10, 2021 7:59 PM EST Volume: 72,713
USD NASD | DELAYED PRICE
SECTOR INDUSTRY
Health Care Biotechnology

A+ Stock Grade Summary:

VALUE:
GROWTH:
MOMENTUM:
EPS REVISIONS:
QUALITY:
COMPANY SUMMARY
Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections in the United States. The company’s lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that is in Phase 2b clinical trial to treat patients with clostridium difficile infections. It also develops ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus (MRSA), vancomycin resistant enterococcus (VRE), and drug-resistant streptococcus pneumoniae (DRSP), as well as B. anthracis. Acurx Pharmaceuticals, Inc. was incorporated in 2017 and is headquartered in Staten Island, New York.

Commentary & Analysis


Financial Summary

Share Statistics ACXP Industry
Median
Percentile
(All Stocks)
Market Cap (Mil) $5.6 $227.8 5%
Shares Out (Mil) 4.3 53.4 13%
Institutional Ownership 77.2% 92.9% 47%
Float (Mil) 5.1 41.2 12%
Beta -2.03 0.95 0%
Avg Daily Volume (000s) 66 513 32%
Price Change
(52-week)
(83.7%) 47.3% 7%
Growth ACXP Industry
Median
Percentile
(All Stocks)
Sales (5yr) na 12.8% na
Net Income (5yr) (11.7%) (10.1%) 27%
EPS (5yr) 18.6% 15.8% 66
Dividends (5yr) na 0.0% na
Cash Flow (5yr) 2.8% (15.7%) 66%
Estimates Qtrly Current
Fiscal
Year
Next
Fiscal
Year
# of Estimates 2 2 2
Current EPS ($0.425) ($1.925) ($1.750)
Month Ago EPS ($0.425) ($1.925) ($1.750)
# Rev Up 1 0 0
# Rev Down 0 1 1
Three Months Ago EPS ($0.455) ($1.970) ($2.130)
Year/Year Chg (19.7%) (63.8%) (64.3%)
Financials ACXP Industry
Median
Percentile
(All Stocks)
Sales (TTM) (Mil) na $37 na
Net Income (TTM) (Mil) ($8) ($44) 31%
EPS (TTM) ($2.783) ($1.500) 12%
Operating Cash Flow (TTM) (Mil) ($6) ($34) 24%
Net Cash Flow (TTM) (Mil) na $2 na
Long-Term Debt (Q1) (Mil) $0 $4 0%
Enterprise Value (Q1) (Mil) ($3) $177 3%
Valuation ACXP Industry
Median
Percentile
(All Stocks)
P/B 0.61 2.22 13%
P/E na 20.4 na
Dividend Yield na 0.0% na
PEG (5yr hist) na 1.1 na
Ratios ACXP Industry
Median
Percentile
(All Stocks)
Gross Margin na 66.9% na
Net Margin na (75.3%) na
ROA (87.6%) (47.1%) 6%
ROE (128.1%) (53.3%) 7%
Liabilities to Assets 25.8% 29.3% 18%
F-Score 3 2 18%

Acurx Pharmaceuticals, Inc. did not pass any screens on 10/27/2026.

Price and market data provided by QuoteMedia and delayed a minimum of 15 minutes unless otherwise indicated. Fundamental data provided by AAII's Stock Investor Pro and S&P Global Market Intelligence and are updated through the previous trading day.

Ⓒ 2026 American Association of Individual Investors